IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA: UPDATED EFFICACY AND SAFETY OF THE RESONATE STUDY WITH UP TO FOUR YEARS OF FOLLOW-UP

被引：0

作者：

Moreno, C. ^{[1
]}

Byrd, J. C. ^{[2
]}

Hillmen, P. ^{[3
]}

O'Brien, S. ^{[4
]}

Barrientos, J. C. ^{[5
]}

Reddy, N. M. ^{[6
]}

Coutre, S. ^{[7
]}

Tam, C. S. ^{[8
,9
]}

Mulligan, S. P. ^{[10
]}

Jaeger, U. ^{[11
]}

Barr, P. M. ^{[12
]}

Furman, R. R. ^{[13
]}

Kipps, T. J. ^{[14
]}

Thornton, P. ^{[15
]}

Montillo, M. ^{[16
]}

Pagel, J. M. ^{[17
]}

Burger, J. A. ^{[18
]}

Jones, J. ^{[2
]}

Dai, S. ^{[19
]}

Vezan, R. ^{[19
]}

James, D. F. ^{[19
]}

Brown, J. R. ^{[20
]}

机构：

[1] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[2] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[3] Leeds Teaching Hosp, St James Inst Oncol, Leeds, W Yorkshire, England

[4] Univ Calif Irvine, Irvine, CA USA

[5] Hofstra Northwell Sch Med, Hempstead, NY USA

[6] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[7] Stanford Univ, Sch Med, Stanford, CA USA

[8] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[9] St Vincents Hosp, Melbourne, Vic, Australia

[10] Royal North Shore Hosp, Sydney, NSW, Australia

[11] Med Univ Vienna, Div Hematol & Hemostaseol, Vienna, Austria

[12] Univ Rochester, Med Ctr, Rochester, NY 14627 USA

[13] Weill Cornell Med Coll, New York, NY USA

[14] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

[15] Beaumont Hosp, Dublin, Ireland

[16] Osped Niguarda Ca Granda, Niguarda Canc Ctr, Milan, Italy

[17] Swedish Canc Inst, Hematol Malignancies Program, Seattle, WA USA

[18] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[19] Pharmacyclics LLC, Sunnyvale, CA USA

[20] Dana Farber Canc Inst, CLL Ctr, Boston, MA 02115 USA

来源：

HAEMATOLOGICA | 2017年 / 102卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

S769

引用

页码：311 / 311

页数：1

共 50 条

[31] Real world efficacy and safety of teriflunomide in multiple sclerosis: an observational study with four years follow-up
Boz, C.
Terzi, M.
Ozakbas, S.
Yuceyar, N.
Efendi, H.
Balci, B. P.
Turkoglu, R.
Karabudak, R.
Soysal, A.
Yetkin, M. F.
Kurne, A.
Akcali, A.
Akman, G.
Demirkiran, M.
Sevim, S.
Kiyioglu, N.
Cilingir, V.
Koseoglu, M.
Uzuner, G.
Omerhoca, S.
Turan, O. F.
Kizilay, F.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 870 - 870
[32] EHA 2021: Up to 7 Years of Follow-up confirms reliable Long-Term Efficacy and safety profile of Ibrutinib
不详
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (7-8) : 432 - 432
[33] Efficacy and Safety of Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia
Cao, Zhijian
Ma, Jun
BLOOD, 2019, 134
[34] MEMBRANOUS NEPHROPATHY ASSOCIATED WITH B CHRONIC LYMPHOCYTIC-LEUKEMIA - A 5 YEARS FOLLOW-UP
BAGLIN, A
PRINSEAU, J
ALTERESCU, R
FRANC, B
NOCHY, D
GOGUEL, A
ANNALES DE MEDECINE INTERNE, 1986, 137 (08): : 692 - 692
[35] Phase 3 study of ibrutinib as first-line treatment in older patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): a 4-year follow-up from the RESONATE-2 study
Burger, J. A.
Barr, P. M.
Robak, T.
Owen, C.
Ghia, P.
Tedeschi, A.
Bairey, O.
Hillmen, P.
Coutre, S. E.
Devereux, S.
Grosicki, S.
McCarthy, H.
Li, J.
Simpson, D.
Offner, F.
Moreno, C.
Dai, S.
Dean, J. P.
James, D. F.
Kipps, T. P.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 29 - 29
[36] Four years follow-up in a naturalistic study of adults with ADHD treated with atomoxetine
Richarte Fernandez, V.
Corrales de la Cruz, M.
Ibanez Jimenez, P.
Corominas Rosso, M.
Vidal Estrada, R.
Fadeuilhe Grau, C.
Palma-Alvarez, R. F.
Casas Brugue, M.
Ramos-Quiroga, J. A.
EUROPEAN PSYCHIATRY, 2016, 33 : S278 - S278
[37] Ibrutinib Treatment in Waldenstrom's Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATE™ Study
Buske, Christian
Tedeschi, Alessandra
Trotman, Judith
Garcia-Sanz, Ramon
MacDonald, David
Leblond, Veronique
Mahe, Beatrice
Herbaux, Charles
Tam, Constantine S.
Palomba, M. Lia
Matous, Jeffrey V.
Shustik, Chaim
Kastritis, Eftathios
Treon, Steven P.
Lih, Chih-Jian
Li, Jianling
Salman, Zeena
Graef, Thorsten
Dimopoulos, Meletios A.
BLOOD, 2018, 132
[38] Prolonged Improvement in Patient-Reported Outcomes and Well-Being in Older Patients With Treatment-Naive Chronic Lymphocytic Leukemia Treated With Ibrutinib: 3-Year Follow-Up of the RESONATE-2 Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (01) : 9 - 10
[39] SFH recommendations for diagnosis, treatment and follow-up of chronic lymphocytic leukemia
Arnoulet, C.
Callet-Bauchu, E.
Cazin, B.
Cahn, J. Y.
Choquet, S.
Colombat, P.
Cymbalista, F.
Davi, F.
Delmer, A.
Divine, M.
Dreyfus, B.
Gachard, N.
Ifrah, N.
Leblond, V.
Leporrier, M.
Lepretre, S.
Levy, V.
Lode, L.
MacIntyre, E.
Khac, F. Nguyen
Remenieras, L.
Sutton, L.
Troussard, X.
Ysebaert, L.
HEMATOLOGIE, 2006, 12 : 22 - 27
[40] THE ADDED VALUE OF PERSONALIZED FOLLOW-UP FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
Bakker, L. J.
Redekop, K.
Aarts, J. E.
VALUE IN HEALTH, 2018, 21 : S41 - S41

← 1 2 3 4 5 →